Clinical Trial Update: A Study to Evaluate the Safest Dose Range for FEIBA in Hemophilia A Patients With Inhibitors on Emicizumab [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial to evaluate the safest dose range for FEIBA in hemophilia A patients with inhibitors who are on emicizumab.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• FEIBA (activated prothrombin complex concentrate)

Snippet

Sponsor: Children's Hospital Los Angeles | Conditions: Hemophilia A With Inhibitor | Phase 4 | Status: ACTIVE_NOT_RECRUITING